Upregulation of BST-2/Tetherin by HIV infection in vivo

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10659-10668

  Homann, Stefanie ^a   Smith, Davey ^a,c   Little, Susan ^a   Richman, Douglas ^a,b,c   Guatelli, John ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; EMTRICITABINE; INTERLEUKIN 6; MEMBRANE PROTEIN; TENOFOVIR; TETHERIN; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VPU PROTEIN;

ARTICLE; B LYMPHOCYTE; BLOOD CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS INHIBITION; VIRUS RELEASE; WILD TYPE;

ANTI-HIV AGENTS; ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELLS, CULTURED; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; UP-REGULATION;

EID: 80054971914     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05524-11     Document Type: Article

References (45)

1. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738.
2. Andrew, A., and K. Strebel. 2011. The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J. Interferon Cytokine Res. 31:137-144.
3. Barr, S. D., J. R. Smiley, and F. D. Bushman. 2008. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 4:e1000007.
4. Baum, A., and A. Garcia-Sastre. 2010. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 38:1283-1299.
5. Beignon, A. S., et al. 2005. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115:3265-3275.
6. Blasius, A. L., et al. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177:3260-3265.
7. Breckpot, K., et al. 2010. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol. 84:5627-5636.
8. Brichacek, B., et al. 2010. Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One 5:e12831.
9. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992. Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-celltropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554.
10. Day, J. R., N. Van Damme, and J. C. Guatelli. 2006. The effect of the membrane-proximal tyrosine-based sorting signal of HIV-1 gp41 on viral infectivity depends on sequences within gp120. Virology 354:316-327.
11. Dejucq, N., and S. G. P. R. Clapham. 2000. T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J. Gen. Virol. 81:2899-2904.
12. Douglas, J. L., et al. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a TrCP-dependent mechanism. J. Virol. 83:7931-7947.
13. Gaines, H., et al. 1990. Immunological changes in primary HIV-1 infection. AIDS 4:995-999.
14. Gottlinger, H. G., T. Dorfman, J. G. Sodroski, and W. A. Haseltine. 1991. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. U. S. A. 88:3195-3199.
15. Heil, F., et al. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529.
16. Hornung, V., et al. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-4537.
17. Jacquelin, B., et al. 2009. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119:3544-3555.
18. Jolly, C., and B. N. S. J. Neil. 2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 84:12185-12199.
19. Kawai, S., et al. 2006. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leuk. Res. 30:949-956.
20. Kornbluth, R. S., P. S. Oh, J. R. Munis, P. H. Cleveland, and D. D. Richman. 1989. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J. Exp. Med. 169:1137-1151.
21. Levy, J. A., I. Scott, and C. Mackewicz. 2003. Protection from HIV/AIDS: the importance of innate immunity. Clin. Immunol. 108:167-174.
22. Martinelli, E., et al. 2007. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 104:3396-3401.
23. Martinson, J. A., et al. 2007. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology 120:526-535.
24. Meylan, E., et al. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172.
25. Miyagi, E., A. J. Andrew, S. Kao, and K. Strebel. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 106:2868-2873.
26. Neil, S. J., V. Sandrin, W. I. Sundquist, and P. D. Bieniasz. 2007. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2:193-203.
27. Neil, S. J., T. Zang, and P. D. Bieniasz. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
28. Ohtomo, T., et al. 1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 19:583-591.
29. Pertel, T., et al. 2011. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361-365.
30. Poli, G., J. M. Orenstein, A. Kinter, T. M. Folks, and A. S. Fauci. 1989. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575-577.
31. Richards, K. H., and P. R. Clapham. 2007. Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages. J. Gen. Virol. 88:2780-2792.
32. Schroder, M., and A. G. Bowie. 2005. TLR3 in antiviral immunity: key player or bystander? Trends Immunol. 26:462-468.
33. Schubert, U., et al. 1998. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:2280-2288.
34. Shah, A. H., et al. 2010. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 8:397-409.
35. Siegal, F. P., P. Fitzgerald-Bocarsly, B. K. Holland, and M. Shodell. 2001. Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 15:1603-1612.
36. Stacey, A. R., et al. 2009. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83:3719-3733.
37. Stephens, E. B., et al. 2002. Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 293: 252-261.
38. Stetson, D. B., and R. Medzhitov. 2006. Type I interferons in host defense. Immunity 25:373-381.
39. Terry, V. H., I. C. Johnston, and C. A. Spina. 2009. CD44 microbeads accelerate HIV-1 infection in T cells. Virology 388:294-304.
40. Tokarev, A., S. M. K. Fitzpatrick, and J. Guatelli. 2009. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res. Hum. Retroviruses 25:1197-1210.
41. van Boxel-Dezaire, A. H., M. R. Rani, and G. R. Stark. 2006. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361-372.
42. Van Damme, N., et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
43. Verthelyi, D., K. J. Ishii, M. Gursel, F. Takeshita, and D. M. Klinman. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 166:2372-2377.
44. von Sydow, M., A. Sonnerborg, H. Gaines, and O. Strannegard. 1991. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res. Hum. Retroviruses 7:375-380.
45. Yan, N., A. D. Regalado-Magdos, B. Stiggelbout, M. A. Lee-Kirsch, and J. Lieberman. 2010. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11:1005-1013.